APA Blogs
36 Results
Collaboration is Key to Meeting Demand for Mental Health Services
The COVID-19 pandemic has left in its wake a serious mental health crisis, the scope of which is still evolving. Even before the pandemic, demand for mental health care services was extremely high, and increasing by the day. Now, as lockdowns have ended and many pandemic restrictions have lifted in America, COVID is still putting a strain on health care personnel, and the systems they work in. In addition to laying bare the severity of healthcare disparities in our communities, the pandemic has also focused a spotlight on the seriousness of the mental health care shortage in America. In the face of these mounting challenges and unprecedented need, it is clear that the future of mental health care in our country will require an interdisciplinary approach.
As Telepsychiatry Options Expand, Patient Safety and Quality Is Essential
A statement from the APA’s Telepsychiatry and Mental Health IT Committees on Patient Safety and Quality
APA Advocacy on Mental Health Legislation Leads to Victory in U.S. House of Representatives
Last month, the U.S. House of Representatives passed H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act. The bill now goes to the U.S. Senate for consideration and deliberation of what measures will be included in a possible mental health legislative package.
Kickoff of APA’s “Looking Beyond Series” Explores the Social Determinants of Mental Health
The social determinants of health and mental health were the focus of a recent APA Mental Health Equity Fireside Chat hosted by APA’s Division of Diversity and Health Equity and moderated by Division Chief and Deputy Medical Director Regina James, M.D.
What APA Is Doing for You: Update on Clozapine REMS
- By Saul Levin, M.D., M.P.A., FRCP-E, FRCPsych
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to monitor prescribing and dispensing of the drug, which is used to treat schizophrenia. The new REMS led to confusion for manufacturers, pharmacies, prescribers, and patients. Some clinicians stopped prescribing the already underutilized drug, and some pharmacies stopped dispensing it. This chaotic situation led the FDA to stop enforcing certain requirements of the REM for 90 days.